1. Home
  2. TLSA vs ENTX Comparison

TLSA vs ENTX Comparison

Compare TLSA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

SELL

Current Price

$0.63

Market Cap

145.1M

Sector

Health Care

ML Signal

SELL

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

SELL

Current Price

$3.29

Market Cap

147.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TLSA
ENTX
Founded
2013
2010
Country
United Kingdom
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
147.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
TLSA
ENTX
Price
$0.63
$3.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$7.81
★ $9.75
AVG Volume (30 Days)
★ 550.9K
228.1K
Earning Date
05-01-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 0.33
Revenue
N/A
★ $42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.94
Revenue Growth
★ N/A
N/A
52 Week Low
$0.55
$0.91
52 Week High
$1.90
$4.20

Technical Indicators

Market Signals
Indicator
TLSA
ENTX
Relative Strength Index (RSI) 40.05 57.67
Support Level $0.57 $2.71
Resistance Level $1.21 $3.26
Average True Range (ATR) 0.09 0.17
MACD 0.01 0.00
Stochastic Oscillator 22.51 56.15

Price Performance

Historical Comparison
TLSA
ENTX

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: